Memantine Hydrochloride Tablet
Product Images NDC 72578-003

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 72578-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viona Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure diagram of Memantine Hydrochloride showing the molecular arrangement including amino (NH2) and hydrochloride (HCl) groups attached to a bicyclic structure with methyl (CH3) substituents.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph showing the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment. The graph compares two groups: Placebo and Memantine Hydrochloride (M.HCl). The vertical axis represents mean change with error bars, labeled from -7 to 2, and the horizontal axis represents weeks of treatment at 0, 4, 12, and 28 weeks. The placebo group shows a decline over time, while the Memantine Hydrochloride group shows less decline, indicating clinical decline and improvement lines.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage curve graph comparing patient response for Memantine Hydrochloride (M.HCl) and placebo. The x-axis represents ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients. Two curves display treatment effect differences over the range of ADCS-ADL scores.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph depicting the mean change from baseline in the SIB score over 28 weeks of treatment. It compares two groups: Placebo (square markers) and Memantine Hydrochloride (M.HCl, circle markers). The y-axis shows mean change with SEM error bars, indicating clinical improvement or decline, while the x-axis represents weeks of treatment.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative incidence plot showing the percentage of patients on the y-axis and SIB (Severe Impairment Battery) change from baseline on the x-axis. The graph compares patients treated with Memantine Hydrochloride (M. HCl) and placebo, distinguished by open circles and solid squares respectively, illustrating cumulative patient response distributions.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph comparing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment for two groups: Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The y-axis shows mean change with standard error, and the x-axis shows weeks of treatment. Data points indicate clinical decline and improvement trends.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline for two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis represents the change in ADCS-ADL scores, and the y-axis shows the cumulative percentage of patients, with data points depicted as squares and circles representing each group, respectively.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph showing the mean change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil groups. The y-axis represents mean change in SIB score with clinical improvement and decline marked. Data points with error bars are plotted at multiple time intervals.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage of patients plot comparing SIB (Severe Impairment Battery) change from baseline between two treatment groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil (M. HCl/Donepezil). The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentages up to 100%.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 10)

Label for Memantine Hydrochloride Tablets, USP 5 mg oral tablets by Viona Pharmaceuticals Inc. The label states a 60 tablet count, prescription use, and includes storage instructions along with manufacturer details for Cadila Healthcare Ltd. The label features a barcode and NDC 72578-003-14.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 11)

Packaging label for Memantine Hydrochloride Tablets, USP 10 mg oral tablets by Viona Pharmaceuticals Inc. The label shows a 60-tablet container listing the NDC 72578-004-14. Storage and dispensing instructions, dosage strength, manufacturer and distributor details are included. Barcode and a designated area for coding are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.